which is under a global license agreement with Organon. Visit www.xaciato.com for information about XACIATO. Daré’s portfolio also includes potential first-in-category candidates in clinical ...

which is under a global license agreement with Organon. Visit www.xaciato.com for information about XACIATO. Daré’s portfolio also includes potential first-in-category candidates in clinical ...

In the first quarter of 2024, through our commercialization agreement with Organon, XACIATO became available by prescription, across the United States. And we have been pleased with Organon's ...

SHANGHAI, China & JERSEY CITY, N.J., May 24, 2024--European Medicines Agency validates Organon and Henlius marketing authorization filings for Prolia and Xgeva (denosumab) biosimilar candidate HLX14.

One such company is Organon & Co (Symbol: OGN), which saw buying by Chief Human Resources Officer Aaron Falcione. Back on May 7, Falcione invested $48,235.00 into 5,500 shares of OGN, for a cost ...

Daré will host a conference call and live webcast today, May 13, 2025, at 4:30 p.m. Eastern Time to review financial results ...

The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil ...